67 Matching Annotations
  1. Last 7 days
  2. Jul 2021
    1. Regev-Yochay, G., Amit, S., Bergwerk, M., Lipsitch, M., Leshem, E., Kahn, R., Lustig, Y., Cohen, C., Doolman, R., Ziv, A., Novikov, I., Rubin, C., Gimpelevich, I., Huppert, A., Rahav, G., Afek, A., & Kreiss, Y. (2021). Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel. The Lancet Regional Health - Europe, 7, 100150. https://doi.org/10.1016/j.lanepe.2021.100150

  3. Jun 2021
    1. Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Gethings, O., Vihta, K.-D., Jones, J., House, T., VanSteenHouse, H., Bell, I., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I., Rourke, E., Studley, R., Crook, D., Peto, T. E. A., Walker, A. S., & Pouwels, K. B. (2021). Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nature Medicine, 1–9. https://doi.org/10.1038/s41591-021-01410-w

  4. May 2021
    1. Eric Topol. (2021, May 1). Downgrading the concern on B.1.617, the poorly named ‘double mutant’—98% effectiveness of mRNA vaccine in an Israeli outbreak @CT_Bergstrom https://t.co/tGbuwPUmAL —Lab studies: Minimal immune evasion, expected full protection from vaccine @GuptaR_lab https://t.co/AIp24G0ROK https://t.co/AK20UWlDBD [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1388539223230140422

    1. David Benkeser. (2020, November 9). Another view on uncertainty associated based on Pfizer’s results. Even if you were highly skeptical about MRNA vaccines (many are [were?]) with 50% prior belief that VE ~ 0, based on an 8:86 vax:placebo case split, the posterior probability that VE > 75% is ~ 1. Https://t.co/xtBONtGHmT [Tweet]. @biosbenk. https://twitter.com/biosbenk/status/1325856366225993729

  5. Apr 2021
  6. Mar 2021
  7. Feb 2021
  8. Jan 2021
  9. Dec 2020
    1. We report the preclinical development of BNT162b2, a lipid-nanoparticle (LNP) formulated N1-methyl-pseudouridine (m1Ψ) nucleoside-modified mRNA (modRNA) vaccine candidate that encodes P2 S with a native furin cleavage site resulting in the S1 and S2 cleavage fragments
    2. To generate the template for RNA synthesis, a DNA fragment encoding the SARS-CoV-2 P2 279 S protein (based on GenBank: MN908947), including the amino acid exchanges K986P and 280 V987P, was cloned into a starting plasmid vector with backbone sequence elements for 281 improved RNA stability and translational efficiency19,34

      BNT162b2

  10. Nov 2020